News | August 25, 2025
GSK forays into oncology in India with Jemperli and Zejula
The company is bringing precision therapies for gynaecological cancers
The company is bringing precision therapies for gynaecological cancers
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
